Results 211 to 220 of about 11,213,687 (295)

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. [PDF]

ESMO Gastrointest Oncol
Ueno M, Ikezawa K, Komatsu Y, Nagano H, Hisano T, Terashima T, Nio K, Morizane C, Shimizu S, Ozaka M, Ohyama H, Otsuru T, Sudo K, Mizuno N, Daniel C, Martín-Fernández L, Amellal N, Bernard K, Sasaki M.   +18 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

ELFT phase II :

, 2009
M Indovina, V Dvornychenko, E Tabassi, G Quinn, P Grother, M Garris, S Meagher   +6 more
openaire   +1 more source

Synthesis of Hydrophobic Derivatives of Stilbenes with Improved Permeability and Limited Phase II Reactions. [PDF]

J Agric Food Chem
Navarro-Orcajada S, Conesa I, Vidal-Sánchez FJ, Matencio A, López-Nicolás JM.   +4 more
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke Ineligible for Recanalization Therapies: A Phase II Trial. [PDF]

Stroke Vasc Interv Neurol
Diamanti S, Tettamanti M, Ornello R, Pedrazzini FA, Farè M, Colangeli E, Tiseo C, Mainini G, Giglio A, Sozzi C, Ferrari F, Beccia M, Bianchi E, Bersano A, Bazzini C, Cartabia M, Zoia CP, Mariani J, Pignataro G, Cavallini A, Sette G, Sacco S, Ferrarese C, Beretta S.   +23 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

phase-6 AG - Analyses and results of initial research studies: An independent report [PDF]

, 2009
Fritz, Catherine O, Fritz, Catherine, Morris, Peter, Passey, Don, Morris, Peter E   +4 more
core